menu
    • menu
    [{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PF-07328948","moa":"[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BMS-770767","moa":"11-beta-HSD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BMS-823778","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"BMS-823778","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"BMS-823778","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CSL_112","moa":"ABCA1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"ABLi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IKT-001PRO","moa":"ABL\/PDGFR?\/PDGFR?\/c-Kit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ABLi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABLi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABLi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KER-012","moa":"ACVR2A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"BAY1067197","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BAY1067197","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Neladenoson Bialanate","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Neladenoson Bialanate","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Medical University of South Carolina \/ Astellas Pharma"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Northwestern University \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ Astellas Pharma"},{"orgOrder":0,"company":"Adenobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Adenosine","moa":"Adenosine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Adenobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adenobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adenobio \/ Undisclosed"},{"orgOrder":0,"company":"New York Medical College","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"New York Medical College","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York Medical College \/ H. Lundbeck AS","highestDevelopmentStatusID":"8","companyTruncated":"New York Medical College \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Labetalol Hydrochloride","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Center for Clinical Research, Winston-Salem, NC","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Center for Clinical Research, Winston-Salem, NC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Center for Clinical Research, Winston-Salem, NC \/ Medtronic plc","highestDevelopmentStatusID":"8","companyTruncated":"Center for Clinical Research, Winston-Salem, NC \/ Medtronic plc"},{"orgOrder":0,"company":"University Hospitals Cleveland Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Hospitals Cleveland Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Cleveland Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University Hospitals Cleveland Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Galway","sponsor":"Health Research Board, Ireland","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Galway","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Galway \/ Health Research Board, Ireland","highestDevelopmentStatusID":"8","companyTruncated":"University of Galway \/ Health Research Board, Ireland"},{"orgOrder":0,"company":"Corimmun","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"COR-1","moa":"Adrenergic receptor beta-1 (ADRB1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Corimmun","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Corimmun \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Corimmun \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APD418","moa":"Adrenergic receptor beta-3 (ADRB3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ SGS Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ SGS Life Sciences"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Talfirastide","moa":"AGTR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Constant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Molnlycke Health Care AB \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"Molnlycke Health Care AB \/ MediWound"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"3M Health Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"3M Health Care \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"3M Health Care \/ MediWound"},{"orgOrder":0,"company":"Translational Sciences, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Translational Sciences, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Sciences, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Translational Sciences, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Translational Sciences, Inc.","sponsor":"University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Translational Sciences, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Sciences, Inc. \/ University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona","highestDevelopmentStatusID":"8","companyTruncated":"Translational Sciences, Inc. \/ University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"National Heart, Lung, and Blood Institute | Cedars-Sinai | Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ National Heart, Lung, and Blood Institute | Cedars-Sinai | Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ National Heart, Lung, and Blood Institute | Cedars-Sinai | Mayo Clinic"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"ISIS 703802","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ TIMI Study Group"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-AGT01","moa":"Angiotensinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"ALN-AGT01","moa":"Angiotensinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION904","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Partnership","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BW-00112","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Argo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"BW-00112","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argo Biopharma","amount2":5.3600000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":5.3600000000000003,"dosageForm":"Injection","sponsorNew":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MEDI5884","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PolyMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PMX-60056","moa":"antagonists of heparin and\/or low molecular weight heparins","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PolyMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyMedix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyMedix \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Eleclazine","moa":"antiarrhythmic\/antianginal\/antihypertensive agents","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Eleclazine","moa":"antiarrhythmic\/antianginal\/antihypertensive agents","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eleclazine","moa":"antiarrhythmic\/antianginal\/antihypertensive agents","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bindarit","moa":"antirheumatics (lobenzarit type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angelini Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"CiVi007","moa":"antisense oligonucleotides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CiVi Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CiVi Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CiVi Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"CiVi007","moa":"antisense oligonucleotides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CiVi Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CiVi Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CiVi Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"University of Cambridge | AstraZeneca | MedImmune","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Apelin","moa":"Apelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ University of Cambridge | AstraZeneca | MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ University of Cambridge | AstraZeneca | MedImmune"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"ISIS apoC-III Rx","moa":"ApoC-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LY3819469","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SLN360","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerenis Therapeutics","sponsor":"South Australian Health and Medical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cerenis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerenis Therapeutics \/ South Australian Health and Medical Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Cerenis Therapeutics \/ South Australian Health and Medical Research Institute"},{"orgOrder":0,"company":"Cerenis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cerenis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerenis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerenis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerenis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cerenis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerenis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerenis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"ISIS 678354","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PL-3994","moa":"Atrial natriuretic peptide receptor A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Ixmyelocel-T","moa":"Autologous bone marrow cells","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vericel Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vericel Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BAY1753011","moa":"AVPR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"David J. Gagnon","sponsor":"MaineHealth | National Institute of General Medical Sciences | University of New England","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Trimethoprim","moa":"Bacterial dihydrofolate reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"David J. Gagnon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David J. Gagnon \/ MaineHealth | National Institute of General Medical Sciences | University of New England","highestDevelopmentStatusID":"8","companyTruncated":"David J. Gagnon \/ MaineHealth | National Institute of General Medical Sciences | University of New England"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"University of Minnesota \/ Forest Laboratories"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Medtronic plc","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Medtronic plc"},{"orgOrder":0,"company":"OvationLab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Beta Glucan","moa":"Beta-glucan receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OvationLab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OvationLab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OvationLab \/ Undisclosed"},{"orgOrder":0,"company":"NHS Greater Glasgow and Clyde","sponsor":"University of Glasgow | NuvOx Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dodecafluoropentane","moa":"Blood gas interface","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS Greater Glasgow and Clyde","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NHS Greater Glasgow and Clyde \/ University of Glasgow | NuvOx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NHS Greater Glasgow and Clyde \/ University of Glasgow | NuvOx Pharma"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"American Heart Association | Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ American Heart Association | Lantheus Medical Imaging","highestDevelopmentStatusID":"8","companyTruncated":"Thomas Jefferson University \/ American Heart Association | Lantheus Medical Imaging"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Perflutren Protein-Type A Microspheres","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GE Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GE Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc"},{"orgOrder":0,"company":"Resverlogix","sponsor":"South Australian Health and Medical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ South Australian Health and Medical Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Resverlogix \/ South Australian Health and Medical Research Institute"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Laval University","sponsor":"Canadian Institutes of Health Research | Resverlogix","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laval University \/ Canadian Institutes of Health Research | Resverlogix","highestDevelopmentStatusID":"8","companyTruncated":"Laval University \/ Canadian Institutes of Health Research | Resverlogix"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Erenumab","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CXL-1020","moa":"Calcium sensitizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CXL-1020","moa":"Calcium sensitizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986435","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CK-4021586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MYK-224","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"L-Arginine","moa":"Cationic amino acid transporter 3; Antizyme inhibitor 2; Argininosuccinate lyase; Nitric oxide synthase, inducible; High affinity cationic amino acid transporter 1; Arginase-2, mitochondrial; Cationic amino acid transporter 4; Argininosuccinate synthase; Nitric oxide synthase 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MLN1202","moa":"C-C chemokine receptor type 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LHW090","moa":"CD10","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"RiboCor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Carbohydrate","year":"2013","type":"Inapplicable","leadProduct":"Ribose","moa":"Cellular energy production","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RiboCor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RiboCor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RiboCor \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"PharmaNet","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"DRL-17822","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ PharmaNet","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ PharmaNet"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2484595","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LY2484595","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Xention Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xention Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xention Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xention Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xention Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xention Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xention Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xention Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xention Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xention Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xention Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xention Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xention Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xention Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xention Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xention Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BAY1142524","moa":"Chymase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fulacimstat","moa":"Chymase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Techfields Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TF0023","moa":"Coagulation factor IIa (F2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Techfields Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Techfields Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Techfields Inc \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"TB-402","moa":"Coagulation factor VIII","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxurion \/ BioInvent","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ BioInvent"},{"orgOrder":0,"company":"Korea University Guro Hospital","sponsor":"Dt&Sanomedics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Korea University Guro Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea University Guro Hospital \/ Dt&Sanomedics","highestDevelopmentStatusID":"8","companyTruncated":"Korea University Guro Hospital \/ Dt&Sanomedics"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAHO Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Universitari de Bellvitge","sponsor":"Spanish Society of Nephrology | Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hospital Universitari de Bellvitge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hospital Universitari de Bellvitge \/ Spanish Society of Nephrology | Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Hospital Universitari de Bellvitge \/ Spanish Society of Nephrology | Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Canadian Institutes of Health Research | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ottawa Hospital Research Institute \/ Canadian Institutes of Health Research | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Ottawa Hospital Research Institute \/ Canadian Institutes of Health Research | Bristol Myers Squibb"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Mayo Clinic \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Population Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Population Health Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Population Health Research Institute"},{"orgOrder":0,"company":"Palak Shah","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palak Shah","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palak Shah \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Palak Shah \/ Abbott Laboratories"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"UMC Utrecht","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ UMC Utrecht","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ UMC Utrecht"},{"orgOrder":0,"company":"Sung-Hwan Kim","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sung-Hwan Kim","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sung-Hwan Kim \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Sung-Hwan Kim \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Asan Medical Center \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bayer AG | Duke Clinical Research Institute | Harvard Medical School (HMS and HSDM)","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bayer AG | Duke Clinical Research Institute | Harvard Medical School (HMS and HSDM)","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bayer AG | Duke Clinical Research Institute | Harvard Medical School (HMS and HSDM)"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anthos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Matrizyme Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matrizyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matrizyme Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matrizyme Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Tesidolumab","moa":"Complement C5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Manchester University NHS FT","sponsor":"National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Trientine Hydrochloride","moa":"Copper","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Manchester University NHS FT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford","highestDevelopmentStatusID":"8","companyTruncated":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cetylsalicylic Acid","moa":"COX-1\/COX-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"JNJ-39588146","moa":"CRHR2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"ISIS CRP Rx","moa":"CRP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Polyphor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Balixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polyphor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polyphor \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University | Hamilton Academic Health Sciences Organization","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Hamilton Health Sciences \/ McMaster University | Hamilton Academic Health Sciences Organization","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ McMaster University | Hamilton Academic Health Sciences Organization"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"St. Boniface Hospital | Health Sciences Centre Winnipeg | University at Buffalo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Manitoba \/ St. Boniface Hospital | Health Sciences Centre Winnipeg | University at Buffalo","highestDevelopmentStatusID":"8","companyTruncated":"University of Manitoba \/ St. Boniface Hospital | Health Sciences Centre Winnipeg | University at Buffalo"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Morgan Stanley"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LFF269","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LFF269","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pradigastat","moa":"Diacylglycerol acyltransferase 1 (DGAT1)||Diacylglycerol O-acyltransferase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pradigastat","moa":"Diacylglycerol O-acyltransferase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Arisaph Pharmaceuticals","sponsor":"Baim Institute for Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ARI-3037MO","moa":"Diacylglycerol O-acyltransferase 2 (DGAT2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arisaph Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arisaph Pharmaceuticals \/ Baim Institute for Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Arisaph Pharmaceuticals \/ Baim Institute for Clinical Research"},{"orgOrder":0,"company":"Arisaph Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ARI-3037MO","moa":"Diacylglycerol O-acyltransferase 2 (DGAT2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arisaph Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arisaph Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arisaph Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Bial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PORTUGAL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zamicastat","moa":"Dopamine beta-hydroxylase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Undisclosed"},{"orgOrder":0,"company":"Bial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PORTUGAL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zamicastat","moa":"Dopamine beta-hydroxylase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Burke Rehabilitation Hospital","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Armodafinil","moa":"Dopamine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Burke Rehabilitation Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burke Rehabilitation Hospital \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"Burke Rehabilitation Hospital \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Laguna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PHILIPPINES","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vanoxerine","moa":"Dopamine transporter (DAT)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Laguna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laguna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laguna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arvid Carlsson Research","sponsor":"Gottfries Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OSU 6162","moa":"Dopamine\/serotonin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arvid Carlsson Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Arvid Carlsson Research \/ Gottfries Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Arvid Carlsson Research \/ Gottfries Clinic"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Recardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recardio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Undisclosed"},{"orgOrder":0,"company":"Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UKRAINE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Arkansas","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cobimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Arkansas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"University of Arkansas \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Arkansas \/ Genentech"},{"orgOrder":0,"company":"D-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SERBIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"THR-18","moa":"Endothelial plasminogen activator inhibitor (SERPINE1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"D-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"D-Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"D-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"D-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SERBIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"THR-18","moa":"Endothelial plasminogen activator inhibitor (SERPINE1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"D-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D-Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"D-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"NHS Greater Glasgow and Clyde","sponsor":"University of Glasgow | King's College London | University of Oxford | Oxford University Hospitals NHS Trust | University of Cambridge | Papworth Hospital NHS Foundation Trust | Blackpool Teaching Hospitals NHS Foundation Trust | Royal Free Hospital NHS F","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Zibotentan","moa":"Endothelin receptor ET-A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS Greater Glasgow and Clyde","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NHS Greater Glasgow and Clyde \/ University of Glasgow | King's College London | University of Oxford | Oxford University Hospitals NHS Trust | University of Cambridge | Papworth Hospital NHS Foundation Trust | Blackpool Teaching Hospitals NHS Foundation Trust | Royal Free Hospital NHS F","highestDevelopmentStatusID":"8","companyTruncated":"NHS Greater Glasgow and Clyde \/ University of Glasgow | King's College London | University of Oxford | Oxford University Hospitals NHS Trust | University of Cambridge | Papworth Hospital NHS Foundation Trust | Blackpool Teaching Hospitals NHS Foundation Trust | Royal Free Hospital NHS F"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ACT-050089","moa":"Endothelin receptor ET-A | Endothelin receptor ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tezosentan","moa":"Endothelin receptor ET-A | Endothelin receptor ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Aarhus University Hospital | Bispebjerg Hospital | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigshospitalet \/ Aarhus University Hospital | Bispebjerg Hospital | Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ Aarhus University Hospital | Bispebjerg Hospital | Johnson & Johnson"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Almac Group | Frontier Science & Technology Research Foundation | Covance | Chiltern International Ltd | WorldCare Clinical, LLC | AcitGraph | Medidata Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Almac Group | Frontier Science & Technology Research Foundation | Covance | Chiltern International Ltd | WorldCare Clinical, LLC | AcitGraph | Medidata Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Almac Group | Frontier Science & Technology Research Foundation | Covance | Chiltern International Ltd | WorldCare Clinical, LLC | AcitGraph | Medidata Solutions"},{"orgOrder":0,"company":"Pharma 2100","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pharma 2100","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharma 2100 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharma 2100 \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"MEDI6012","moa":"enzymes; steroids (androgens","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"MEDI6012","moa":"enzymes; steroids (androgens","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"MEDI6012","moa":"enzymes; steroids (androgens","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ TIMI Study Group"},{"orgOrder":0,"company":"Columbia University","sponsor":"MedImmune | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"MEDI6012","moa":"enzymes; steroids (androgens","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ MedImmune | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ MedImmune | AstraZeneca"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BIIB131","moa":"EPHX2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Ajou University School of Medicine","sponsor":"Dong-A Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ajou University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajou University School of Medicine \/ Dong-A Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ajou University School of Medicine \/ Dong-A Pharmaceutical"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Asundexian","moa":"F11a||FXIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FEIBA","moa":"Factor VIII","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MAA868","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MAA868","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthos Therapeutics \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Anthos Therapeutics \/ Covance"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Calcium channel unspecific (CaC)||Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Calcium channel unspecific (CaC)||Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Quotient Sciences","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Quotient Sciences"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"LLG783","moa":"FGFR1\/FGFR2\/FGFR3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Plasmin","moa":"Fibrinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ University of California, Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ University of California, Los Angeles"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"8","companyTruncated":"Xuanwu Hospital, Beijing \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"Elixir Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Elixir Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elixir Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elixir Medical \/ Undisclosed"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"National University Heart Centre, Singapore","sponsor":"AstraZeneca | University of Otago","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZD5718","moa":"FLAP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National University Heart Centre, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National University Heart Centre, Singapore \/ AstraZeneca | University of Otago","highestDevelopmentStatusID":"8","companyTruncated":"National University Heart Centre, Singapore \/ AstraZeneca | University of Otago"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AZD5718","moa":"FLAP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"AZD5718","moa":"FLAP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"AZD5718","moa":"FLAP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AZD5718","moa":"FLAP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AZD5718","moa":"FLAP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rostafuroxin","moa":"fluoroquinolone derivatives","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RostaQuo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rostafuroxin","moa":"fluoroquinolone derivatives","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RostaQuo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RostaQuo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RostaQuo \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"ISIS-FXIRx","moa":"FXI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Basmisanil","moa":"GABA(A) receptor alpha-5 (GABRA5)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ponsegromab","moa":"monoclonal antibodies: mouse","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ TIMI Study Group"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Danegaptide","moa":"aptamers","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Doer Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Junbo Ge","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1|GCG|FGF21 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Junbo Ge","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Junbo Ge"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Albiglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Health Network, Toronto \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ AstraZeneca"},{"orgOrder":0,"company":"Neuroscience Trials Australia","sponsor":"National Health and Medical Research Council, Australia | Monash University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Neuroscience Trials Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuroscience Trials Australia \/ National Health and Medical Research Council, Australia | Monash University","highestDevelopmentStatusID":"8","companyTruncated":"Neuroscience Trials Australia \/ National Health and Medical Research Council, Australia | Monash University"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercator MedSystems \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Undisclosed"},{"orgOrder":0,"company":"Fluoropharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bfpet","moa":"Glucose metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Fluoropharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fluoropharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fluoropharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"GSK1292263","moa":"Glucose-dependent insulinotropic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Population Health Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Population Health Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"AMO Pharma \/ Population Health Research Institute"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Population Health Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Population Health Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"AMO Pharma \/ Population Health Research Institute"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Population Health Research Institute | Canadian Institutes of Health Research | AMO Pharma | Hearts in Rhythm Organization | Canadian SADS","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Population Health Research Institute | Canadian Institutes of Health Research | AMO Pharma | Hearts in Rhythm Organization | Canadian SADS","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Population Health Research Institute | Canadian Institutes of Health Research | AMO Pharma | Hearts in Rhythm Organization | Canadian SADS"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"BC 007","moa":"GPCR\/?-adrenoceptors","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berlin Cures \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Undisclosed"},{"orgOrder":0,"company":"Reponex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"Granulocyte colony stimulating factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reponex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Reponex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reponex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinevant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Intervene Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Intervene Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intervene Immune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intervene Immune \/ Undisclosed"},{"orgOrder":0,"company":"Marc Sakwa, MD","sponsor":"Essential Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L-Histidine","moa":"H2-receptor antagonists (cimetidine type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marc Sakwa, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marc Sakwa, MD \/ Essential Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Marc Sakwa, MD \/ Essential Pharma"},{"orgOrder":0,"company":"CellProthera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Hematopoetic Stem Cell","moa":"Hematopoietic stem cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CellProthera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellProthera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CellProthera \/ Undisclosed"},{"orgOrder":0,"company":"CellProthera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Hematopoetic Stem Cell","moa":"Hematopoietic stem cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CellProthera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellProthera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CellProthera \/ Undisclosed"},{"orgOrder":0,"company":"Martin Andreas, M.D.","sponsor":"National Bank of Austria | Orphan Medical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Heme Arginate","moa":"Heme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Martin Andreas, M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Martin Andreas, M.D. \/ National Bank of Austria | Orphan Medical","highestDevelopmentStatusID":"8","companyTruncated":"Martin Andreas, M.D. \/ National Bank of Austria | Orphan Medical"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TrueBinding \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Undisclosed"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ropocamptide","moa":"Hepatitis B virus membrane","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Promore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Amiodarone Hydrochloride","moa":"HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"VM202","moa":"HGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"Northwestern University","sponsor":"National Institute on Aging | Helixmith","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"VM202","moa":"HGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwestern University \/ National Institute on Aging | Helixmith","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ National Institute on Aging | Helixmith"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"VM202RY","moa":"HGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"VM202RY","moa":"HGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Martin-Luther-Universit\u00e4t Halle-Wittenberg \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Martin-Luther-Universit\u00e4t Halle-Wittenberg \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Texas Heart Institute | AstraZeneca | InfraReDx","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Texas Heart Institute | AstraZeneca | InfraReDx","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Texas Heart Institute | AstraZeneca | InfraReDx"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Cleveland Clinic \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Cleveland Clinic \/ AstraZeneca"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Pegylated Carboxyhemoglobin Bovine","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prolong Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"National Heart, Lung, and Blood Institute | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Perfluorobutane","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ National Heart, Lung, and Blood Institute | GE Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Thomas Jefferson University \/ National Heart, Lung, and Blood Institute | GE Healthcare"},{"orgOrder":0,"company":"Nepean Blue Mountains LHD","sponsor":"Innogene Kalbiotech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sodium Lactate","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Nepean Blue Mountains LHD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nepean Blue Mountains LHD \/ Innogene Kalbiotech","highestDevelopmentStatusID":"8","companyTruncated":"Nepean Blue Mountains LHD \/ Innogene Kalbiotech"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Meridian Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Caprylic Acid","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Meridian Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Virginia Commonwealth University \/ Meridian Bioscience"},{"orgOrder":0,"company":"Sanifit","sponsor":"Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SNF472","moa":"Hydroxyapatite (HA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanifit \/ Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Sanifit \/ Clinipace Worldwide"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Daprodustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Silver Creek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"scp776","moa":"IGF-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silver Creek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silver Creek \/ Undisclosed"},{"orgOrder":0,"company":"Silver Creek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Scp776","moa":"IGF-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silver Creek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silver Creek \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MAS825","moa":"IL-1?","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Pacibekitug","moa":"IL6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.3999999999999999,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tourmaline Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Undisclosed"},{"orgOrder":0,"company":"International University of Health and Welfare","sponsor":"Japan Agency for Medical Research and Development | Keio University | Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"International University of Health and Welfare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International University of Health and Welfare \/ Japan Agency for Medical Research and Development | Keio University | Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"International University of Health and Welfare \/ Japan Agency for Medical Research and Development | Keio University | Chugai Pharmaceutical"},{"orgOrder":0,"company":"Albireo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Albireo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albireo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Albireo \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pinocembrin","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Eurotrials Brasil","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Ruscus Extract","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Eurotrials Brasil","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Eurotrials Brasil"},{"orgOrder":0,"company":"Cell Therapy Ltd.","sponsor":"Royal Brompton & Harefield NHS FT","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Immunomodulatory Progenitor Cell","moa":"Immune progenitor cells","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cell Therapy Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell Therapy Ltd. \/ Royal Brompton & Harefield NHS FT","highestDevelopmentStatusID":"8","companyTruncated":"Cell Therapy Ltd. \/ Royal Brompton & Harefield NHS FT"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ubenimex","moa":"immunostimulants","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ubenimex","moa":"immunostimulants","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CeleCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"St. Antonius Hospital | Diagram","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CeleCor Therapeutics \/ St. Antonius Hospital | Diagram","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ St. Antonius Hospital | Diagram"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Precision For Medicine | CirQuest Labs | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CeleCor Therapeutics \/ Precision For Medicine | CirQuest Labs | Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ Precision For Medicine | CirQuest Labs | Syneos Health"},{"orgOrder":0,"company":"Grand Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Grand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grand Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grand Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medicure","sponsor":"SCRI Development Innovations, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicure \/ SCRI Development Innovations, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/ SCRI Development Innovations, LLC"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Abciximab","moa":"Integrin alpha-IIb\/beta-3 | Integrin alpha-V\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"Siemens Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Radiolabeled Compound","year":"2012","type":"Inapplicable","leadProduct":"18-F RDG-K5","moa":"Integrin-alpha-V-beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Siemens Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siemens Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Siemens Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"KPL-914","moa":"Interleukin-1 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"St. Olavs Hospital | South-Eastern Norway Regional Health Authority | University of Oslo | Norwegian University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ St. Olavs Hospital | South-Eastern Norway Regional Health Authority | University of Oslo | Norwegian University of Science and Technology","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ St. Olavs Hospital | South-Eastern Norway Regional Health Authority | University of Oslo | Norwegian University of Science and Technology"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"St. Olavs Hospital | South-Eastern Norway Regional Health Authority | University of Oslo | Norwegian University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ St. Olavs Hospital | South-Eastern Norway Regional Health Authority | University of Oslo | Norwegian University of Science and Technology","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ St. Olavs Hospital | South-Eastern Norway Regional Health Authority | University of Oslo | Norwegian University of Science and Technology"},{"orgOrder":0,"company":"Papworth Hospital NHS Foundation Trust","sponsor":"F. Hoffmann-La Roche | National Institute for Health Research, UK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Papworth Hospital NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Papworth Hospital NHS Foundation Trust \/ F. Hoffmann-La Roche | National Institute for Health Research, UK","highestDevelopmentStatusID":"8","companyTruncated":"Papworth Hospital NHS Foundation Trust \/ F. Hoffmann-La Roche | National Institute for Health Research, UK"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"SB-480848","moa":"LDL-associated phospholipase A2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MEDI6570","moa":"Lectin-like oxidized LDL receptor (OLR1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ TIMI Study Group"},{"orgOrder":0,"company":"Genentech","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MLDL1278A","moa":"LILRB4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ BioInvent","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ BioInvent"},{"orgOrder":0,"company":"Valbiotis","sponsor":"TP ICAP Midcap","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Public Offering","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ TP ICAP Midcap","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ TP ICAP Midcap"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ 5Am Ventures"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"HRS-5346","moa":"Lipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":1.97,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.97,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Muvalaplin","moa":"Apolipoprotein(a) (LPA)||LPA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Muvalaplin","moa":"LPA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Pelacarsen","moa":"LPA mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ACT-280778","moa":"L-type calcium channel\/T-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"Dart Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"HT-3951","moa":"MAO-B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Dart Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dart Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dart Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"CervoMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAP kinase p38 alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Undisclosed"},{"orgOrder":0,"company":"AZTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Cromoglicate","moa":"Heat shock protein HSP 90-alpha; Protein S100-P||MasT-cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AZTherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AZTherapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AZTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Cadrock Pty. Ltd.","sponsor":"Centre for Digestive Diseases, Australia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cadrock Pty. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cadrock Pty. Ltd. \/ Centre for Digestive Diseases, Australia","highestDevelopmentStatusID":"8","companyTruncated":"Cadrock Pty. Ltd. \/ Centre for Digestive Diseases, Australia"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FCN-159","moa":"MEK1 \/ MEK2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Xuanwu Hospital, Beijing \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Action Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"AP214","moa":"Melanocortin receptor 1 | Melanocortin receptor 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Action Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Action Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Action Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Ami Multistem Cell","moa":"Mesenchymal stem cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AZD9977","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZD9977","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AZD9977","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZD9977","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZD9977","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"NHS National Waiting Times Centre Board","sponsor":"British Heart Foundation | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS National Waiting Times Centre Board","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NHS National Waiting Times Centre Board \/ British Heart Foundation | Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"NHS National Waiting Times Centre Board \/ British Heart Foundation | Abbott Laboratories"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LY2623091","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1100000000000001,"dosageForm":"Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Cardior Pharmaceuticals \/ INKEF Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ INKEF Capital"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardior Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardior Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardior Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Aldagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"ALD-401","moa":"Mitochondrial aldehyde dehydrogenase (ALDH2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aldagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aldagen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldagen \/ Undisclosed"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"Flurpiridaz","moa":"Mitochondrial complex I","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GE Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GE Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Universidade do Porto","sponsor":"Centro Hospitalar de Vila Nova de Gaia\/Espinho | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PORTUGAL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Universidade do Porto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidade do Porto \/ Centro Hospitalar de Vila Nova de Gaia\/Espinho | Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Universidade do Porto \/ Centro Hospitalar de Vila Nova de Gaia\/Espinho | Merck Group"},{"orgOrder":0,"company":"Stanford University","sponsor":"Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Western Sydney Local Health District","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Western Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western Sydney Local Health District \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Western Sydney Local Health District \/ Undisclosed"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Xuanwu Hospital, Beijing \/ Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TRO40303","moa":"Mitochondrial permeability transition pore","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ European Commission","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ European Commission"},{"orgOrder":0,"company":"Danisco","sponsor":"University of Turku | 4Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ University of Turku | 4Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Danisco \/ University of Turku | 4Pharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Selonsertib","moa":"Mitogen-activated protein kinase kinase kinase 5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Southeast Renal Research Institute","sponsor":"Dialysis Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Southeast Renal Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Southeast Renal Research Institute \/ Dialysis Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Southeast Renal Research Institute \/ Dialysis Clinic"},{"orgOrder":0,"company":"Sinphar Pharmaceuticals Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Green Tea Polyphenol","moa":"Multiple (e.g., EGFR, NF-?B)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sinphar Pharmaceuticals Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sinphar Pharmaceuticals Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sinphar Pharmaceuticals Co \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"GSK249320","moa":"Myelin-associated glycoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AZD4831","moa":"Myeloperoxidase (MPO)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Copenhagen \/ Elysium Health"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Exemed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"VASCage GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Cerebrolysin","moa":"Neurotrophic factor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ VASCage GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Ever Pharma \/ VASCage GmbH"},{"orgOrder":0,"company":"Aires Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AIR001","moa":"Nitrite","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aires Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Aires Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aires Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BMS-986231","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"CXL-1427","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Cardioxyl Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CXL-1427","moa":"nitrogen oxide (eg.","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Cardioxyl Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DFV890","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Zomagen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VTX2735","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zomagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zomagen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zomagen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Zhejiang Apeloa Jiayuan Pharmaceutical | Subei People's Hospital | The First Hospital of Jilin University | First Hospital of China Medical University | General Hospital of Shenyang Military Region | The First Affiliated Hospital of BaoTou Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Salfaprodil","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Tiantan Hospital \/ Zhejiang Apeloa Jiayuan Pharmaceutical | Subei People's Hospital | The First Hospital of Jilin University | First Hospital of China Medical University | General Hospital of Shenyang Military Region | The First Affiliated Hospital of BaoTou Medical College","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Zhejiang Apeloa Jiayuan Pharmaceutical | Subei People's Hospital | The First Hospital of Jilin University | First Hospital of China Medical University | General Hospital of Shenyang Military Region | The First Affiliated Hospital of BaoTou Medical College"},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Salfaprodil","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GNT Pharma \/ Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"GNT Pharma \/ Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LMI 1195","moa":"Norepinephrine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lantheus Medical Imaging \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantheus Medical Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Saroglitazar magnesium","moa":"NR1C","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Complexa","sponsor":"Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Complexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complexa \/ Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/ Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute"},{"orgOrder":0,"company":"Complexa","sponsor":"Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Complexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complexa \/ Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/ Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute"},{"orgOrder":0,"company":"Mark Gladwin","sponsor":"National Heart, Lung, and Blood Institute | Complexa","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mark Gladwin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mark Gladwin \/ National Heart, Lung, and Blood Institute | Complexa","highestDevelopmentStatusID":"8","companyTruncated":"Mark Gladwin \/ National Heart, Lung, and Blood Institute | Complexa"},{"orgOrder":0,"company":"Abcentra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Orticumab","moa":"Oxidized LDL","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Abcentra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abcentra \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abcentra \/ Undisclosed"},{"orgOrder":0,"company":"HonorHealth Research Institute","sponsor":"Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Dual Antiplatelet Therapy","moa":"P2Y12 receptor \/ COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HonorHealth Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HonorHealth Research Institute \/ Boston Scientific","highestDevelopmentStatusID":"8","companyTruncated":"HonorHealth Research Institute \/ Boston Scientific"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Modified Release","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Modified Release","sponsorNew":"Imbria Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CervoMed","sponsor":"University of California, Los Angeles | University of Virginia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CervoMed \/ University of California, Los Angeles | University of Virginia","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ University of California, Los Angeles | University of Virginia"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9||Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Fortrea"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9||Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9||Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9||Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9||Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9||Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MPSK3169A","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"Cemdisiran","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Charite University, Berlin, Germany | SCIRENT Clinical Research and Science d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Charite University, Berlin, Germany | SCIRENT Clinical Research and Science d.o.o.","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Charite University, Berlin, Germany | SCIRENT Clinical Research and Science d.o.o."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-54452840","moa":"peptides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Capricor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Cenderitide","moa":"peptides: atrial natriuretic type substances","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Capricor \/ Undisclosed"},{"orgOrder":0,"company":"Capricor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Cenderitide","moa":"peptides: atrial natriuretic type substances","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Capricor \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Research Institute, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kowa Research Institute, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Research Institute, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Research Institute, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Research Institute, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kowa Research Institute, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Research Institute, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Research Institute, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ZYH7","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Genfit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genfit \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ Undisclosed"},{"orgOrder":0,"company":"University of Massachusetts, Worcester","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rosiglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Massachusetts, Worcester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Massachusetts, Worcester \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"University of Massachusetts, Worcester \/ GSK"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ascension Health \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Phosphodiesterase 3A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Korea Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Phosphodiesterase 3A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Korea Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Korea Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"South-Eastern Norway Regional Health Authority | Norwegian Health Association | Norwegian Association for Children with Congenital Heart Disease","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | Norwegian Health Association | Norwegian Association for Children with Congenital Heart Disease","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | Norwegian Health Association | Norwegian Association for Children with Congenital Heart Disease"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"PF-00489791","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"PF-03049423","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"Phosphodiesterase 9 (PDE9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"Phosphodiesterase 9 (PDE9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Imara","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Imara","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Imara"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Ascenta Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Ascenta Capital"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"University Hospital, Basel","sponsor":"Swiss National Science Foundation | Pharming","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Hospital, Basel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital, Basel \/ Swiss National Science Foundation | Pharming","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Basel \/ Swiss National Science Foundation | Pharming"},{"orgOrder":0,"company":"Pharming","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Desmoteplase","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LT-3001","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lumosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Thrombolytic Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Mutant Pro-Urokinase","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Thrombolytic Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thrombolytic Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Thrombolytic Science \/ Undisclosed"},{"orgOrder":0,"company":"TMS","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"TMS-007","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TMS","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"TMS \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"TMS \/ Biogen"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vicagrel","moa":"platelet aggregation inhibitors","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Deutsches Herzzentrum Muenchen","sponsor":"Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung | AdvanceCor | Technical University of Munich | German Federal Ministry of Education and Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Revacept","moa":"Platelet glycoprotein VI (GP6)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Deutsches Herzzentrum Muenchen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deutsches Herzzentrum Muenchen \/ Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung | AdvanceCor | Technical University of Munich | German Federal Ministry of Education and Research","highestDevelopmentStatusID":"8","companyTruncated":"Deutsches Herzzentrum Muenchen \/ Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung | AdvanceCor | Technical University of Munich | German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"advanceCOR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Revacept","moa":"Platelet glycoprotein VI (GP6)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"advanceCOR","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"advanceCOR \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"advanceCOR \/ Undisclosed"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"The University of Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"Platelet glycoprotein VI (GPVI)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acticor Biotech SAS \/ The University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Biotech SAS \/ The University of Birmingham"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"University of Birmingham","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Glenzocimab","moa":"Platelet glycoprotein VI (GPVI)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acticor Biotech SAS \/ University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Biotech SAS \/ University of Birmingham"},{"orgOrder":0,"company":"Jakob Stensballe","sponsor":"Cellphire Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jakob Stensballe","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jakob Stensballe \/ Cellphire Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jakob Stensballe \/ Cellphire Therapeutics"},{"orgOrder":0,"company":"Jeil Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"JPI-289","moa":"Poly [ADP-ribose] polymerase-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jeil Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeil Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jeil Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MST-188","moa":"polymers","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vepoloxamer","moa":"polymers","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Relypsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Relypsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relypsa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Relypsa \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Michael Fu","sponsor":"AstraZeneca | G\u00f6teborg University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Michael Fu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael Fu \/ AstraZeneca | G\u00f6teborg University","highestDevelopmentStatusID":"8","companyTruncated":"Michael Fu \/ AstraZeneca | G\u00f6teborg University"},{"orgOrder":0,"company":"Essentialis","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diazoxide","moa":"ABCC8(SUR1)\/KCNJ11(KIR6.2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Essentialis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essentialis \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Essentialis \/ Medpace, Inc"},{"orgOrder":0,"company":"Essentialis","sponsor":"Cetero Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diazoxide","moa":"ABCC8(SUR1)\/KCNJ11(KIR6.2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Essentialis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essentialis \/ Cetero Research","highestDevelopmentStatusID":"8","companyTruncated":"Essentialis \/ Cetero Research"},{"orgOrder":0,"company":"Xintong Pharmacy Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xintong Pharmacy Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xintong Pharmacy Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xintong Pharmacy Company \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"AskBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Undisclosed"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"National University Health System, Singapore","sponsor":"National Medical Research Council, Singapore | NattoPharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Menaquinone-7","moa":"Pregnane X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National University Health System, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National University Health System, Singapore \/ National Medical Research Council, Singapore | NattoPharma","highestDevelopmentStatusID":"8","companyTruncated":"National University Health System, Singapore \/ National Medical Research Council, Singapore | NattoPharma"},{"orgOrder":0,"company":"CardioCell","sponsor":"Stemedica Cell Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Bone Marrow Cell","moa":"Progenitor cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CardioCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CardioCell \/ Stemedica Cell Technologies","highestDevelopmentStatusID":"8","companyTruncated":"CardioCell \/ Stemedica Cell Technologies"},{"orgOrder":0,"company":"ReNeuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CTX0E03","moa":"Progenitor cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ReNeuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ReNeuron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReNeuron \/ Undisclosed"},{"orgOrder":0,"company":"ReNeuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CTX0E03","moa":"Progenitor cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ReNeuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ReNeuron \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReNeuron \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"ImmuneCare Biopharmaceuticals | The First Affiliated Hospital of Nanyang Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMC-001","moa":"Programmed cell death 1 ligand 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneOnco \/ ImmuneCare Biopharmaceuticals | The First Affiliated Hospital of Nanyang Medical College","highestDevelopmentStatusID":"8","companyTruncated":"ImmuneOnco \/ ImmuneCare Biopharmaceuticals | The First Affiliated Hospital of Nanyang Medical College"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIB Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"LIB Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIB Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LIB Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIB Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"LIB Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MK-0616","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heidelberg University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Heidelberg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Heidelberg University \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Heidelberg University \/ Bayer AG"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Liquidia Corporation \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Liquidia Corporation \/ FGK Clinical Research"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ United Therapeutics"},{"orgOrder":0,"company":"Ken Mahaffey","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vorapaxar Sulfate","moa":"Proteinase-activated receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ken Mahaffey","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ken Mahaffey \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Ken Mahaffey \/ Merck & Co"},{"orgOrder":0,"company":"Ischemix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"CMX-2043","moa":"Proto-oncogene c-Met (MET)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ischemix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ischemix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ischemix \/ Undisclosed"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Constant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biocells (Beijing) Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BXOS110","moa":"PSD95","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biocells (Beijing) Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocells (Beijing) Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biocells (Beijing) Biotech \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"RO4905417","moa":"P-selectin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"RO4905417","moa":"P-selectin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Tetherex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"SelK2","moa":"P-selectin glycoprotein ligand 1 (SELPLG)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tetherex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetherex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tetherex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"TIMI Study Group","sponsor":"Bristol Myers Squibb | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TIMI Study Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TIMI Study Group \/ Bristol Myers Squibb | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"TIMI Study Group \/ Bristol Myers Squibb | Sanofi"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Selatogrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hellenic Cardiovascular Research Society","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GREECE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hellenic Cardiovascular Research Society","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Cardiovascular Research Society \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Hellenic Cardiovascular Research Society \/ AstraZeneca"},{"orgOrder":0,"company":"Uppsala University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Uppsala University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Uppsala University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Uppsala University \/ AstraZeneca"},{"orgOrder":0,"company":"Papworth Hospital NHS Foundation Trust","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Papworth Hospital NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Papworth Hospital NHS Foundation Trust \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Papworth Hospital NHS Foundation Trust \/ AstraZeneca"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ AstraZeneca"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Seung-Jung Park","sponsor":"AstraZeneca | F. Hoffmann-La Roche | KBM Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Seung-Jung Park","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seung-Jung Park \/ AstraZeneca | F. Hoffmann-La Roche | KBM Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Seung-Jung Park \/ AstraZeneca | F. Hoffmann-La Roche | KBM Pharm"},{"orgOrder":0,"company":"Yochai Birnbaum","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Yochai Birnbaum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yochai Birnbaum \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Yochai Birnbaum \/ AstraZeneca"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"JTT-251","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JTT-861","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akros Pharma \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Icon Plc"},{"orgOrder":0,"company":"Cardiovascular Clinical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Alagebrium","moa":"quaternary ammonium derivatives","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiovascular Clinical Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiovascular Clinical Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiovascular Clinical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Cromos Pharma | Data Management 365 | Keystat | R-Pharm | K-Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ Cromos Pharma | Data Management 365 | Keystat | R-Pharm | K-Research","highestDevelopmentStatusID":"8","companyTruncated":"R-Pharm \/ Cromos Pharma | Data Management 365 | Keystat | R-Pharm | K-Research"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AZD5462","moa":"Relaxin receptor 1 (RXFP1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AZD5462","moa":"Relaxin receptor 1 (RXFP1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Quotient Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Quotient Sciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Relaxin-2 protein, human","moa":"Relaxin receptor 1 | Relaxin receptor 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sir Mortimer B. Davis - Jewish General Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aliskiren","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sir Mortimer B. Davis - Jewish General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sir Mortimer B. Davis - Jewish General Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Sir Mortimer B. Davis - Jewish General Hospital \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Afimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DS102","moa":"Reperfusion stress","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Afimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Undisclosed"},{"orgOrder":0,"company":"Afimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Epeleuton","moa":"Reperfusion stress","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Afimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"Repulsive guidance molecule A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SAR407899","moa":"Rho-associated protein kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LY3540378","moa":"RXFP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BMS-986259","moa":"RXFP1\/RXFP2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Sequel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"K201","moa":"Ryanodine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sequel Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sequel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sequel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"K201","moa":"Ryanodine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sequel Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sequel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ARM210","moa":"RYR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARMGO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Celladon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Mydicar","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 (ATP2A2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Celladon","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Celladon"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Chang Gung University","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Chang Gung University","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Chang Gung University"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Momentum Research Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Windtree Therapeutics \/ Momentum Research Inc","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Momentum Research Inc"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"JVS-100","moa":"SDF-1 (CXCL12)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Juventas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juventas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novasep","sponsor":"Celladon","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"AAV1-SERCA2a","moa":"SERCA2a||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novasep","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Novasep \/ Celladon","highestDevelopmentStatusID":"8","companyTruncated":"Novasep \/ Celladon"},{"orgOrder":0,"company":"Celladon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AAV1-SERCA2a","moa":"SERCA2a","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celladon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celladon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celladon \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Temanogrel","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Temanogrel","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"University of British Columbia | Sunnybrook Health Sciences Centre | University of Calgary | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview Health Centre Foundation | Memorial University of Newfoundland | Applied Health Research Cen","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ University of British Columbia | Sunnybrook Health Sciences Centre | University of Calgary | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview Health Centre Foundation | Memorial University of Newfoundland | Applied Health Research Cen","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ University of British Columbia | Sunnybrook Health Sciences Centre | University of Calgary | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview Health Centre Foundation | Memorial University of Newfoundland | Applied Health Research Cen"},{"orgOrder":0,"company":"NoNO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NoNO-42","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NoNO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NoNO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NoNO \/ Undisclosed"},{"orgOrder":0,"company":"NoNO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NoNO-42","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NoNO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"NoNO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NoNO \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Sunnybrook Health Sciences Centre | Mount Sinai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Mount Sinai Hospital","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Mount Sinai Hospital"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Pennsylvania \/ Amgen Inc"},{"orgOrder":0,"company":"Mari\u00eblle Scheffer","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mari\u00eblle Scheffer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mari\u00eblle Scheffer \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Mari\u00eblle Scheffer \/ AstraZeneca"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AP30663","moa":"SK ion channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acesion Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AP30663","moa":"SK ion channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acesion Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Phosphatidyl Choline Cu\/Zn Superoxide Dismutase","moa":"SOD1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Tide Pharmaceutical \/ Peking University First Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tide Pharmaceutical \/ Peking University First Hospital"},{"orgOrder":0,"company":"IRCCS San Raffaele","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"IRCCS San Raffaele","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRCCS San Raffaele \/ Menarini","highestDevelopmentStatusID":"8","companyTruncated":"IRCCS San Raffaele \/ Menarini"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"North Florida Foundation for Research and Education","sponsor":"Gilead Sciences | University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"North Florida Foundation for Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"North Florida Foundation for Research and Education \/ Gilead Sciences | University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"North Florida Foundation for Research and Education \/ Gilead Sciences | University of Florida"},{"orgOrder":0,"company":"North Florida Foundation for Research and Education","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"North Florida Foundation for Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"North Florida Foundation for Research and Education \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"North Florida Foundation for Research and Education \/ Gilead Sciences"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"University of Rochester \/ Gilead Sciences"},{"orgOrder":0,"company":"Kent Hospital, Rhode Island","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kent Hospital, Rhode Island","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kent Hospital, Rhode Island \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Kent Hospital, Rhode Island \/ Gilead Sciences"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intermountain Health \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Intermountain Health \/ Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"University Medicine G\u00f6ttingen, Cardiac Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ University Medicine G\u00f6ttingen, Cardiac Center","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ University Medicine G\u00f6ttingen, Cardiac Center"},{"orgOrder":0,"company":"Harvey Hahn","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Harvey Hahn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvey Hahn \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Harvey Hahn \/ Gilead Sciences"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ranolazine","moa":"Sodium channel protein type V alpha subunit | Sodium channel protein type IV alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Gilead Sciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"scPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ scPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ scPharmaceuticals"},{"orgOrder":0,"company":"Christian Schulze","sponsor":"Boehringer Ingelheim GmbH | Center for Clinical Studies Jena","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Christian Schulze","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Christian Schulze \/ Boehringer Ingelheim GmbH | Center for Clinical Studies Jena","highestDevelopmentStatusID":"8","companyTruncated":"Christian Schulze \/ Boehringer Ingelheim GmbH | Center for Clinical Studies Jena"},{"orgOrder":0,"company":"Yale University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Merck & Co"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rancho Santa Fe Bio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Ataciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Rancho Santa Fe Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Rancho Santa Fe Bio"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sanofi | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ataciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Sanofi | National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Sanofi | National Institutes of Health"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cinaciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cinaciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cinaciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Indiana University School of Medicine","sponsor":"Mallinckrodt Pharmaceuticals | National Institutes of Health | University of Mississippi Medical Center | University of Texas, Southwestern Medical Center at Dallas | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Indiana University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana University School of Medicine \/ Mallinckrodt Pharmaceuticals | National Institutes of Health | University of Mississippi Medical Center | University of Texas, Southwestern Medical Center at Dallas | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University School of Medicine \/ Mallinckrodt Pharmaceuticals | National Institutes of Health | University of Mississippi Medical Center | University of Texas, Southwestern Medical Center at Dallas | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Steven Messe","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Steven Messe","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steven Messe \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Steven Messe \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Cameron Dezfulian","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cameron Dezfulian","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cameron Dezfulian \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cameron Dezfulian \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Cyclerion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Praliciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Cyclerion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Akebia Therapeutics \/ Cyclerion Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Riociguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Merck & Co | Canadian VIGOUR Centre | Duke Clinical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Merck & Co | Canadian VIGOUR Centre | Duke Clinical Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Merck & Co | Canadian VIGOUR Centre | Duke Clinical Research Institute"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johns Hopkins University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Verinurad","moa":"Solute carrier family 22 member 12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Chemi SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chemi SpA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemi SpA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chemi SpA \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gemcabene","moa":"SREBP pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CAT-2003","moa":"SREBP-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CAT-2003","moa":"SREBP-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CAT-2054","moa":"SREBP-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CAT-2054","moa":"SREBP-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catabasis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"King's College Hospital NHS Trust","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"177-Lu Dotatate","moa":"SSTR2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"King's College Hospital NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"King's College Hospital NHS Trust \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"8","companyTruncated":"King's College Hospital NHS Trust \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Kardigan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Tonlamarsen","moa":"STAT3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kardigan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kardigan \/ Undisclosed"},{"orgOrder":0,"company":"Ever Supreme Bio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ever Supreme Bio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ever Supreme Bio Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ever Supreme Bio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bococizumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Halozyme Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Amgen Inc"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Amgen Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"LY3015014","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"LY3015014","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cereno Scientific \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedy Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Remedy Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"University of Maryland | Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedy Pharmaceuticals \/ University of Maryland | Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Remedy Pharmaceuticals \/ University of Maryland | Massachusetts General Hospital"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"AGN-151607","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Jeffrey Rade","sponsor":"American Heart Association | Cumberland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jeffrey Rade","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jeffrey Rade \/ American Heart Association | Cumberland Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jeffrey Rade \/ American Heart Association | Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Metolazone","moa":"Thiazide-sensitive sodium-chloride cotransporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Scripps Health \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HSK31679","moa":"THR-?","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSK31679","moa":"THR-?","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Johannes Gutenberg University Mainz","sponsor":"Boehringer Ingelheim GmbH | Atrial Fibrillation Network","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johannes Gutenberg University Mainz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johannes Gutenberg University Mainz \/ Boehringer Ingelheim GmbH | Atrial Fibrillation Network","highestDevelopmentStatusID":"8","companyTruncated":"Johannes Gutenberg University Mainz \/ Boehringer Ingelheim GmbH | Atrial Fibrillation Network"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"JNJ-64179375","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"211915-06-9","moa":"thrombin inhibitors (argatroban type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"211915-06-9","moa":"thrombin inhibitors (argatroban type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"211915-06-9","moa":"thrombin inhibitors (argatroban type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Resmetirom","moa":"Thyroid hormone receptor beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Madrigal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"VK2809","moa":"Thyroid hormone receptor beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Genentech"},{"orgOrder":0,"company":"Jacobs Neurological Institute","sponsor":"University at Buffalo, Neurosurgery | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jacobs Neurological Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jacobs Neurological Institute \/ University at Buffalo, Neurosurgery | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Jacobs Neurological Institute \/ University at Buffalo, Neurosurgery | Genentech"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Texas Health Science Center at Houston \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas Health Science Center at Houston \/ Genentech"},{"orgOrder":0,"company":"Lee Schwamm","sponsor":"National Institute of Neurological Disorders and Stroke | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lee Schwamm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Schwamm \/ National Institute of Neurological Disorders and Stroke | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Lee Schwamm \/ National Institute of Neurological Disorders and Stroke | Genentech"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Vancouver General Hospital | Ottawa Hospital Research Institute | Hopital Charles Lemoyne | Universit\u00e9 de Sherbrooke | Vancouver Island Health Authority | CHU de Quebec-Universite Laval","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Vancouver General Hospital | Ottawa Hospital Research Institute | Hopital Charles Lemoyne | Universit\u00e9 de Sherbrooke | Vancouver Island Health Authority | CHU de Quebec-Universite Laval","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ Vancouver General Hospital | Ottawa Hospital Research Institute | Hopital Charles Lemoyne | Universit\u00e9 de Sherbrooke | Vancouver Island Health Authority | CHU de Quebec-Universite Laval"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ Genentech"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Genentech"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Pennsylvania \/ Genentech"},{"orgOrder":0,"company":"Melbourne Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Melbourne Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melbourne Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Melbourne Health \/ Undisclosed"},{"orgOrder":0,"company":"Neuroscience Trials Australia","sponsor":"The Florey Institute of Neuroscience and Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Neuroscience Trials Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroscience Trials Australia \/ The Florey Institute of Neuroscience and Mental Health","highestDevelopmentStatusID":"8","companyTruncated":"Neuroscience Trials Australia \/ The Florey Institute of Neuroscience and Mental Health"},{"orgOrder":0,"company":"Neuroscience Trials Australia","sponsor":"The Florey Institute of Neuroscience and Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Neuroscience Trials Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroscience Trials Australia \/ The Florey Institute of Neuroscience and Mental Health","highestDevelopmentStatusID":"8","companyTruncated":"Neuroscience Trials Australia \/ The Florey Institute of Neuroscience and Mental Health"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vanderbilt University Medical Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Vanderbilt University Medical Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Shanghai Zhongshan Hospital","sponsor":"Beijing Continent Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai Zhongshan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Zhongshan Hospital \/ Beijing Continent Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zhongshan Hospital \/ Beijing Continent Pharmaceutical"},{"orgOrder":0,"company":"National Institute for Health Research","sponsor":"Manchester University NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute for Health Research \/ Manchester University NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"National Institute for Health Research \/ Manchester University NHS Foundation Trust"},{"orgOrder":0,"company":"Manchester University NHS FT","sponsor":"National Institute for Health Research, UK | University of Manchester | University of Liverpool | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Manchester University NHS FT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ National Institutes of Health"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"GSK2798745","moa":"Transient receptor potential cation channel subfamily V member 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK2798745","moa":"Transient receptor potential cation channel subfamily V member 4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Lebanese American University","sponsor":"Omicron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"LEBANON","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lebanese American University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lebanese American University \/ Omicron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lebanese American University \/ Omicron Pharmaceuticals"},{"orgOrder":0,"company":"Hopital St. Georges, Ajaltoun","sponsor":"Omicron Pharmaceuticals | NattoPharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"LEBANON","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hopital St. Georges, Ajaltoun","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hopital St. Georges, Ajaltoun \/ Omicron Pharmaceuticals | NattoPharma","highestDevelopmentStatusID":"8","companyTruncated":"Hopital St. Georges, Ajaltoun \/ Omicron Pharmaceuticals | NattoPharma"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altavant Sciences | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Altavant Sciences \/ Altavant Sciences | PPD","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Altavant Sciences | PPD"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Takeda Pharmaceutical | Detiger Funds","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayo Clinic \/ Takeda Pharmaceutical | Detiger Funds","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Takeda Pharmaceutical | Detiger Funds"},{"orgOrder":0,"company":"Gadjah Mada University","sponsor":"Spectranetics Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDONESIA","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gadjah Mada University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gadjah Mada University \/ Spectranetics Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gadjah Mada University \/ Spectranetics Corporation"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Candesartan Cilexetil","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Candesartan Cilexetil","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Rong Zhang","sponsor":"National Institute on Aging | Texas Health Resources | Michigan State University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rong Zhang","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rong Zhang \/ National Institute on Aging | Texas Health Resources | Michigan State University","highestDevelopmentStatusID":"8","companyTruncated":"Rong Zhang \/ National Institute on Aging | Texas Health Resources | Michigan State University"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Olmesartan Medoxomil","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Bundang Hospital \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olmesartan Medoxomil","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Valsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Undisclosed"},{"orgOrder":0,"company":"Genervon Biopharmaceuticals","sponsor":"University of California, Los Angeles | Huntington Hospital | Hoag Memorial Hospital Presbyterian | Columbia University | California Pacific Medical Center Research Institute | University Hospital Erlangen | Sarasota Memorial Hospital | University of Loui","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GM602","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Genervon Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genervon Biopharmaceuticals \/ University of California, Los Angeles | Huntington Hospital | Hoag Memorial Hospital Presbyterian | Columbia University | California Pacific Medical Center Research Institute | University Hospital Erlangen | Sarasota Memorial Hospital | University of Loui","highestDevelopmentStatusID":"8","companyTruncated":"Genervon Biopharmaceuticals \/ University of California, Los Angeles | Huntington Hospital | Hoag Memorial Hospital Presbyterian | Columbia University | California Pacific Medical Center Research Institute | University Hospital Erlangen | Sarasota Memorial Hospital | University of Loui"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Thymosin Beta-4","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Serodus","sponsor":"Smerud Medical Research International AS | The Research Council of Norway","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"SER100","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Serodus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serodus \/ Smerud Medical Research International AS | The Research Council of Norway","highestDevelopmentStatusID":"8","companyTruncated":"Serodus \/ Smerud Medical Research International AS | The Research Council of Norway"},{"orgOrder":0,"company":"ThromBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TBO-309","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ThromBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThromBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ThromBio \/ Undisclosed"},{"orgOrder":0,"company":"Vivacell Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Etribnabdione","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacell Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivacell Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivacell Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Innervate Radiopharmaceuticals","sponsor":"University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F Meta Fluorobenzylguanidine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Innervate Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innervate Radiopharmaceuticals \/ University of Texas System","highestDevelopmentStatusID":"8","companyTruncated":"Innervate Radiopharmaceuticals \/ University of Texas System"},{"orgOrder":0,"company":"AskBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AB-1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Undisclosed"},{"orgOrder":0,"company":"AskBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AB-1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Undisclosed"},{"orgOrder":0,"company":"NHS Greater Glasgow and Clyde","sponsor":"University of Glasgow | Aurum Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ABL-101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS Greater Glasgow and Clyde","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"NHS Greater Glasgow and Clyde \/ University of Glasgow | Aurum Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"NHS Greater Glasgow and Clyde \/ University of Glasgow | Aurum Biosciences"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Optigenex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"AC-11","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Optigenex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Optigenex, Inc"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"Salus Ltd.","sponsor":"TheraVitae Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Acp","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salus Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salus Ltd. \/ TheraVitae Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Salus Ltd. \/ TheraVitae Ltd."},{"orgOrder":0,"company":"Hemostemix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"ACP-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hemostemix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemostemix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hemostemix \/ Undisclosed"},{"orgOrder":0,"company":"Hemostemix","sponsor":"Mcgill University Health Centre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"ACP-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hemostemix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemostemix \/ Mcgill University Health Centre","highestDevelopmentStatusID":"8","companyTruncated":"Hemostemix \/ Mcgill University Health Centre"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD209","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"AD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AK102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ AD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ AD Pharmaceuticals"},{"orgOrder":0,"company":"Akeso","sponsor":"AD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AK102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ AD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ AD Pharmaceuticals"},{"orgOrder":0,"company":"Akeso","sponsor":"AD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AK102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ AD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ AD Pharmaceuticals"},{"orgOrder":0,"company":"Akeso","sponsor":"AD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AK102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ AD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ AD Pharmaceuticals"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"National Heart, Lung, and Blood Institute | Aldagen | Center for Cell and Gene Therapy, Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ALD-301","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Texas Health Science Center at Houston \/ National Heart, Lung, and Blood Institute | Aldagen | Center for Cell and Gene Therapy, Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas Health Science Center at Houston \/ National Heart, Lung, and Blood Institute | Aldagen | Center for Cell and Gene Therapy, Baylor College of Medicine"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"RHEACELL \/ FGK Clinical Research"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","highestDevelopmentStatusID":"8","companyTruncated":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting"},{"orgOrder":0,"company":"Cell2Cure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cell2Cure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cell2Cure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cell2Cure \/ Undisclosed"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","sponsor":"Grupo Pedro Ja\u00e9n","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Grupo Pedro Ja\u00e9n","highestDevelopmentStatusID":"8","companyTruncated":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Grupo Pedro Ja\u00e9n"},{"orgOrder":0,"company":"Joshua M. Hare","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Joshua M. Hare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Joshua M. Hare \/ The Emmes Company, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Joshua M. Hare \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"CardioCell","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemedica Cell Technologies \/ CardioCell","highestDevelopmentStatusID":"8","companyTruncated":"Stemedica Cell Technologies \/ CardioCell"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stempeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"APL-9796","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apollo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Athera Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ATH3G10","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Athera Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athera Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Athera Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"CellPraxis","sponsor":"Cryopraxis | German Center for Diabetes Research | University of South Florida","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Autologous Bone Marrow Mononuclear Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CellPraxis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CellPraxis \/ Cryopraxis | German Center for Diabetes Research | University of South Florida","highestDevelopmentStatusID":"8","companyTruncated":"CellPraxis \/ Cryopraxis | German Center for Diabetes Research | University of South Florida"},{"orgOrder":0,"company":"Manipal Acunova","sponsor":"Ministry of Science and Technology, India","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Manipal Acunova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manipal Acunova \/ Ministry of Science and Technology, India","highestDevelopmentStatusID":"8","companyTruncated":"Manipal Acunova \/ Ministry of Science and Technology, India"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"Cytopeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Bone Marrow-Derived Mononuclear Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National University of Malaysia \/ Cytopeutics","highestDevelopmentStatusID":"8","companyTruncated":"National University of Malaysia \/ Cytopeutics"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous CD133+ stem cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Health Network, Toronto \/ Miltenyi Biotec","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hokkaido University","sponsor":"RAINBOW Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Autologous Mescenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hokkaido University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hokkaido University \/ RAINBOW Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Hokkaido University \/ RAINBOW Inc."},{"orgOrder":0,"company":"Lifecells, LLC.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Autologous Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lifecells, LLC.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lifecells, LLC. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lifecells, LLC. \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AZD2927","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Longview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Longview Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Longview Ventures"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BI765845","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BIII-890","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BMS-914392","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Lundquist Institute for Biomedical Innovation","sponsor":"Lung Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"BPS-314d-MR","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lundquist Institute for Biomedical Innovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lundquist Institute for Biomedical Innovation \/ Lung Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Lundquist Institute for Biomedical Innovation \/ Lung Biotechnology"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Adventa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Breastmilk","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Adventa Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Adventa Biosciences"},{"orgOrder":0,"company":"Dongzhimen Hospital, Beijing","sponsor":"The Affiliated Hospital of Changchun University of Chinese Medicine | The Affiliated Hospital of Shandong University of Chinese Medicine | The Affiliated Hospital of Chengdu University of Chinese Medicine | The Second Affiliated Hospital of Tianjin Univer","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Buqitongluo","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Dongzhimen Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Dongzhimen Hospital, Beijing \/ The Affiliated Hospital of Changchun University of Chinese Medicine | The Affiliated Hospital of Shandong University of Chinese Medicine | The Affiliated Hospital of Chengdu University of Chinese Medicine | The Second Affiliated Hospital of Tianjin Univer","highestDevelopmentStatusID":"8","companyTruncated":"Dongzhimen Hospital, Beijing \/ The Affiliated Hospital of Changchun University of Chinese Medicine | The Affiliated Hospital of Shandong University of Chinese Medicine | The Affiliated Hospital of Chengdu University of Chinese Medicine | The Second Affiliated Hospital of Tianjin Univer"},{"orgOrder":0,"company":"National University of Singapore","sponsor":"A*STAR | AMILI Pte. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Ca-Akg","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National University of Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"National University of Singapore \/ A*STAR | AMILI Pte. Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"National University of Singapore \/ A*STAR | AMILI Pte. Ltd."},{"orgOrder":0,"company":"Fluoropharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cardiopet","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Fluoropharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fluoropharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fluoropharma \/ Undisclosed"},{"orgOrder":0,"company":"Micropharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Cardioviva Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Micropharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micropharma Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Micropharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Micropharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Cardioviva Yogurt","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Micropharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micropharma Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Micropharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Monash University","sponsor":"Monash Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"L-Carnosine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monash University \/ Monash Health","highestDevelopmentStatusID":"8","companyTruncated":"Monash University \/ Monash Health"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorbent Therapeutics","sponsor":"Pharmaterra","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"CAS 133762-83-1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sorbent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorbent Therapeutics \/ Pharmaterra","highestDevelopmentStatusID":"8","companyTruncated":"Sorbent Therapeutics \/ Pharmaterra"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CLR325","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Azienda Ospedaliero-Universitaria di Parma","sponsor":"DOC generici srl","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Coleosoma","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Azienda Ospedaliero-Universitaria di Parma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azienda Ospedaliero-Universitaria di Parma \/ DOC generici srl","highestDevelopmentStatusID":"8","companyTruncated":"Azienda Ospedaliero-Universitaria di Parma \/ DOC generici srl"},{"orgOrder":0,"company":"Corteria Pharmaceuticals","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"COR-1167","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Corteria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corteria Pharmaceuticals \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Corteria Pharmaceuticals \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"HONYA Medical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Cord Blood Nucleated Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HONYA Medical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HONYA Medical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HONYA Medical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Ceapro Inc. | Montreal Health Innovations Coordinating Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CP105F","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montreal Heart Institute \/ Ceapro Inc. | Montreal Health Innovations Coordinating Center","highestDevelopmentStatusID":"8","companyTruncated":"Montreal Heart Institute \/ Ceapro Inc. | Montreal Health Innovations Coordinating Center"},{"orgOrder":0,"company":"RSPR Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"CRD007","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RSPR Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RSPR Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RSPR Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CRD-4730","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardurion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sorbent Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cross-Linked Polyelectrolyte","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sorbent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorbent Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sorbent Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorbent Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cross-Linked Polyelectrolyte","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sorbent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorbent Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sorbent Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"CSL112","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"CSL112","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Franz K\u00f6hler Chemie GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Custodiol-N","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Dr. Franz K\u00f6hler Chemie GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Franz K\u00f6hler Chemie GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Franz K\u00f6hler Chemie GmbH \/ Undisclosed"},{"orgOrder":0,"company":"CVI Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CVI-LM001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CVI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"CVI Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CVI Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYP-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PharmaDiall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimolegin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PharmaDiall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaDiall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaDiall \/ Undisclosed"},{"orgOrder":0,"company":"Dart Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DNS-3379","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Dart Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dart Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dart Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DS-9231","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DW-3102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bota Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Ecklonia Cava Phlorotannin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bota Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bota Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bota Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Yoko Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Nanjing Yoko Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanjing Yoko Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nanjing Yoko Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bournemouth University","sponsor":"Efamol Ltd | Sylvia Waddilove Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Efamol Active 50+","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bournemouth University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bournemouth University \/ Efamol Ltd | Sylvia Waddilove Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Bournemouth University \/ Efamol Ltd | Sylvia Waddilove Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Enclitide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Dutch Heart Foundation | Dutch Kidney Foundation | Microvascular Health Solutions LLC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Endocalyx Pro","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Dutch Heart Foundation | Dutch Kidney Foundation | Microvascular Health Solutions LLC","highestDevelopmentStatusID":"8","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Dutch Heart Foundation | Dutch Kidney Foundation | Microvascular Health Solutions LLC"},{"orgOrder":0,"company":"Energenesis Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ENERGI-F703","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Energenesis Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Energenesis Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Energenesis Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Evazarsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Evazarsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"F373280","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"LongStar HealthPro, Inc. DBA Farlong Pharmaceutical","sponsor":"Yunnan Panlong Yunhai Pharmaceutical Group Co., Ltd. | KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Farlong Ginseng","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LongStar HealthPro, Inc. DBA Farlong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LongStar HealthPro, Inc. DBA Farlong Pharmaceutical \/ Yunnan Panlong Yunhai Pharmaceutical Group Co., Ltd. | KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"LongStar HealthPro, Inc. DBA Farlong Pharmaceutical \/ Yunnan Panlong Yunhai Pharmaceutical Group Co., Ltd. | KGK Science"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Kellogg Company | University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Fibre","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Kellogg Company | University of Toronto","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Kellogg Company | University of Toronto"},{"orgOrder":0,"company":"BIO-CAT","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"GFA-918","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BIO-CAT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BIO-CAT \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"BIO-CAT \/ KGK Science"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Beijing Bionovo Medicine Development","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Ginkgo Diterpene Lactone Meglumine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Tiantan Hospital \/ Beijing Bionovo Medicine Development","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Beijing Bionovo Medicine Development"},{"orgOrder":0,"company":"Beijing Northland Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gletimbetasin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Northland Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Northland Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Northland Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Gwo Xi Stem Cell Applied Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GXNPC1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gwo Xi Stem Cell Applied Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gwo Xi Stem Cell Applied Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gwo Xi Stem Cell Applied Technology \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"H001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"HCP1803","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-7249","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-7249","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Human Fibrinogen Concentrate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ CSL Behring"},{"orgOrder":0,"company":"StemCyte","sponsor":"StemCyte","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Umbilical Cord Blood Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCyte \/ StemCyte","highestDevelopmentStatusID":"8","companyTruncated":"StemCyte \/ StemCyte"},{"orgOrder":0,"company":"Shenzhen Wingor Biotechnology Co., Ltd.","sponsor":"Beijing Tiantan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shenzhen Wingor Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Wingor Biotechnology Co., Ltd. \/ Beijing Tiantan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Wingor Biotechnology Co., Ltd. \/ Beijing Tiantan Hospital"},{"orgOrder":0,"company":"Norwegian Underwater Intervention (NUI)","sponsor":"Western Norway University of Applied Sciences | Helse-Bergen","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hyperbaric Oxygen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Norwegian Underwater Intervention (NUI)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norwegian Underwater Intervention (NUI) \/ Western Norway University of Applied Sciences | Helse-Bergen","highestDevelopmentStatusID":"8","companyTruncated":"Norwegian Underwater Intervention (NUI) \/ Western Norway University of Applied Sciences | Helse-Bergen"},{"orgOrder":0,"company":"Bastiaan Driehuys","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Hyperpolarized Xenon-129","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bastiaan Driehuys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bastiaan Driehuys \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bastiaan Driehuys \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Celixir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"iMP Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celixir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celixir \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celixir \/ Undisclosed"},{"orgOrder":0,"company":"Innolife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"INL1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Innolife","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innolife \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innolife \/ Undisclosed"},{"orgOrder":0,"company":"InVasc Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"INV-144","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"InVasc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InVasc Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InVasc Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"ISIS 757456","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"ISIS 757456","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Jia Shen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Jia Shen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"JMKX003142","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jemincare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Undisclosed"},{"orgOrder":0,"company":"Kunming Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KPCXM18","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kunming Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kunming Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kunming Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Micropharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"L. Reuteri NCIMB 30242","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Micropharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micropharma Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Micropharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Micropharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri NCIMB 30242","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Micropharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micropharma Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Micropharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LC28-0126","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LC28-0126","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lumosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lumosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lumosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lumosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LTP001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LTP001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LTP001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"OcuNexus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2010","type":"Inapplicable","leadProduct":"Lufepirsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OcuNexus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dressing","sponsorNew":"OcuNexus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuNexus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kyttaro","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Kyttaro","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Kyttaro"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Kitasato University","sponsor":"Aetas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"M201-A","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kitasato University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitasato University \/ Aetas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kitasato University \/ Aetas Pharma"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Mayo Clinic | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-Star Biotech \/ Mayo Clinic | PPD","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Mayo Clinic | PPD"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ TIMI Study Group"},{"orgOrder":0,"company":"Marealis AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Marealis Refined Peptide Concentrate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marealis AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marealis AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marealis AS \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"Marealis AS","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Marealis Refined Peptide Concentrate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KGK Science \/ Marealis AS","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Marealis AS"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Public Offering","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ BTIG"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Mesenchymal Precursor Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Quovadis Associazione","sponsor":"Neopharmed Gentili","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mesoglycan","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Quovadis Associazione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quovadis Associazione \/ Neopharmed Gentili","highestDevelopmentStatusID":"8","companyTruncated":"Quovadis Associazione \/ Neopharmed Gentili"},{"orgOrder":0,"company":"Shaanxi Micot Technology Limited Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MT1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shaanxi Micot Technology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shaanxi Micot Technology Limited Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shaanxi Micot Technology Limited Company \/ Undisclosed"},{"orgOrder":0,"company":"Shaanxi Micot Technology Limited Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MT1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shaanxi Micot Technology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shaanxi Micot Technology Limited Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shaanxi Micot Technology Limited Company \/ Undisclosed"},{"orgOrder":0,"company":"Shaanxi Micot Technology Limited Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MT1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shaanxi Micot Technology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shaanxi Micot Technology Limited Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shaanxi Micot Technology Limited Company \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NBS10","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"Neogenis Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Neo40 Daily","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Neogenis Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Neogenis Laboratories"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NKPL66","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Grace Therapeutics \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Grace Therapeutics \/ JSS Medical Research"},{"orgOrder":0,"company":"Beijing Northland Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NL005","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Northland Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Northland Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Northland Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NNC0385-0434","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NNC0385-0434","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NNC0385-0434","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"NNC6019","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Prothena","amount2":1.2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NNC6019-0001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC6019-0001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Medinox","sponsor":"Europharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"NOX-100","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medinox","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medinox \/ Europharma","highestDevelopmentStatusID":"8","companyTruncated":"Medinox \/ Europharma"},{"orgOrder":0,"company":"Armaron Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"NP202","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Armaron Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armaron Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armaron Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NST-1024","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NorthSea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NST-1024","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NorthSea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OMEICOS Therapeutics GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"OMT-28","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OMEICOS Therapeutics GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OMEICOS Therapeutics GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OMEICOS Therapeutics GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OPC 131461","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"OPC-131461","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OPL-0301","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FINLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ORM-12471","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"URUGUAY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Palingen Flow","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amnio Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"URUGUAY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Palingen Flow Amniotic Tissue Allograft","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amnio Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"L-Nutra | Peak Human Labs","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Peak Human Labs Calorie Mimetic Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ L-Nutra | Peak Human Labs","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ L-Nutra | Peak Human Labs"},{"orgOrder":0,"company":"Celularity","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Placenta Derived Cell PDA001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Celgene Corporation"},{"orgOrder":0,"company":"Jennifer Cowger , MD, MS","sponsor":"POM Wonderful","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Pomegranate Polyphenol Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jennifer Cowger , MD, MS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jennifer Cowger , MD, MS \/ POM Wonderful","highestDevelopmentStatusID":"8","companyTruncated":"Jennifer Cowger , MD, MS \/ POM Wonderful"},{"orgOrder":0,"company":"Seqens","sponsor":"CellProthera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2025","type":"Agreement","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Seqens","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqens \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"Seqens \/ CellProthera"},{"orgOrder":0,"company":"CellProthera","sponsor":"BioCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CellProthera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellProthera \/ BioCardia","highestDevelopmentStatusID":"8","companyTruncated":"CellProthera \/ BioCardia"},{"orgOrder":0,"company":"BioCardia","sponsor":"CellProthera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCardia \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"BioCardia \/ CellProthera"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"QCC374","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"QCC374","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QCZ484","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QCZ484","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QLC7401","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLC7401","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"ACCESS Community Health Network | University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Quartet","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ ACCESS Community Health Network | University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ ACCESS Community Health Network | University of Sydney"},{"orgOrder":0,"company":"River 2 Renal Corp.","sponsor":"International HealthCare","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"R2R01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"River 2 Renal Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"River 2 Renal Corp. \/ International HealthCare","highestDevelopmentStatusID":"8","companyTruncated":"River 2 Renal Corp. \/ International HealthCare"},{"orgOrder":0,"company":"Ribocure Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RBD4059","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ribocure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribocure Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ribocure Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ribocure Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RBD5044","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ribocure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribocure Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ribocure Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tasly Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Prourokinase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tasly Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tasly Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tasly Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"DiaMedica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Angde Biotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human Tissue-Type Plasminogen Activator","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Angde Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angde Biotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angde Biotech Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Angde Biotech Pharmaceutical","sponsor":"Beijing Tiantan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Plasminogen Activator","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Angde Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angde Biotech Pharmaceutical \/ Beijing Tiantan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Angde Biotech Pharmaceutical \/ Beijing Tiantan Hospital"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Redasemtide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN7544","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN9933","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN9933","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Reven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Icon Plc | ERT: Clinical Trial Technology Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reven Pharmaceuticals \/ Icon Plc | ERT: Clinical Trial Technology Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Icon Plc | ERT: Clinical Trial Technology Solutions"},{"orgOrder":0,"company":"Relaxera Pharmazeutische","sponsor":"CBL- Chemical and Biopharmaceutical Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Relaxin-2 protein, human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Relaxera Pharmazeutische","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relaxera Pharmazeutische \/ CBL- Chemical and Biopharmaceutical Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Relaxera Pharmazeutische \/ CBL- Chemical and Biopharmaceutical Laboratories"},{"orgOrder":0,"company":"Retension Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"RTN-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Retension Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Retension Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Retension Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Retension Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RTN-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Retension Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Retension Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Retension Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ResoTher Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RTP-026","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ResoTher Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ResoTher Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ResoTher Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"S 44819","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Ilkos Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"S42909","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ilkos Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ilkos Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ilkos Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARM210","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMGO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Bard Medical Division","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Bard Medical Division","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Bard Medical Division"},{"orgOrder":0,"company":"Harald Becher","sponsor":"Alberta Health services | University of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Harald Becher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Harald Becher \/ Alberta Health services | University of Alberta","highestDevelopmentStatusID":"8","companyTruncated":"Harald Becher \/ Alberta Health services | University of Alberta"},{"orgOrder":0,"company":"SanBio","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"SB623","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Sumitomo Pharma America","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"SanBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"SB623","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Beijing Tiantan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHPL-49","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hutchmed \/ Beijing Tiantan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Beijing Tiantan Hospital"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SHR-1209","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-2004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-2004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"San Francisco VA Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Soluble Corn Fiber","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ San Francisco VA Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ San Francisco VA Health Care System"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SPC 1001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPC1001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SPC1001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"SRM003","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"SRW","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"SRW Cel System","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TruDiagnostic \/ SRW","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ SRW"},{"orgOrder":0,"company":"Sinphar Pharmaceuticals Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"STA-2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sinphar Pharmaceuticals Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sinphar Pharmaceuticals Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sinphar Pharmaceuticals Co \/ Undisclosed"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Stempeucel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stempeutics \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SUN13837","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Syneos Health"},{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Undisclosed"},{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Undisclosed"},{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Undisclosed"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SMITH & NEPHEW INC \/ Healiva","highestDevelopmentStatusID":"8","companyTruncated":"SMITH & NEPHEW INC \/ Healiva"},{"orgOrder":0,"company":"SerenaGroup, Inc.","sponsor":"TR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TR 987","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SerenaGroup, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SerenaGroup, Inc. \/ TR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SerenaGroup, Inc. \/ TR Therapeutics"},{"orgOrder":0,"company":"Cortria","sponsor":"Montreal Heart Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"TRIA-662","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cortria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cortria \/ Montreal Heart Institute","highestDevelopmentStatusID":"8","companyTruncated":"Cortria \/ Montreal Heart Institute"},{"orgOrder":0,"company":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TSG-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tectonic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"E-Star Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Undisclosed"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"E-Star Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Undisclosed"},{"orgOrder":0,"company":"SanBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vasomera","moa":"Helodermin-preferring VIP receptor (VIPR2)||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vivacelle Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Vivacelle Bio \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ US Navy"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Viena II 160\/10","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"XRP0038","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"XRP0038","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"XRP0038","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XTR003","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XTR004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Peking University WBL Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Xuezhikang","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Peking University WBL Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Peking University WBL Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Peking University WBL Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XXB750","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XXB750","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Y-6","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Beijing Inno Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YN001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Inno Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Inno Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Inno Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Diao Jiuhong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zhibitai","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chengdu Diao Jiuhong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu Diao Jiuhong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Diao Jiuhong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HSY244","moa":"Unknown","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Geneticure, LLC","sponsor":"Fairview Health Services | University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"HTN Therapy","moa":"Unknown","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Geneticure, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geneticure, LLC \/ Fairview Health Services | University of Minnesota","highestDevelopmentStatusID":"8","companyTruncated":"Geneticure, LLC \/ Fairview Health Services | University of Minnesota"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Angelini Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angelini Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mount Sinai Hospital, Canada","sponsor":"Sunnybrook Health Sciences Centre | McMaster Children's Hospital | The Rotunda Hospital | John Hunter Hospital | Royal Alexandra Hospital | Centre Hospitalier de l'Universite Laval | Royal North Shore Hospital | Prince of Wales Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mount Sinai Hospital, Canada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mount Sinai Hospital, Canada \/ Sunnybrook Health Sciences Centre | McMaster Children's Hospital | The Rotunda Hospital | John Hunter Hospital | Royal Alexandra Hospital | Centre Hospitalier de l'Universite Laval | Royal North Shore Hospital | Prince of Wales Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Mount Sinai Hospital, Canada \/ Sunnybrook Health Sciences Centre | McMaster Children's Hospital | The Rotunda Hospital | John Hunter Hospital | Royal Alexandra Hospital | Centre Hospitalier de l'Universite Laval | Royal North Shore Hospital | Prince of Wales Hospital"},{"orgOrder":0,"company":"Humacyte","sponsor":"Atlantic Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Atlantic Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Atlantic Research Group"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Texas Health Resources | Michigan State University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Texas Health Resources | Michigan State University","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Texas Health Resources | Michigan State University"},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"National Heart, Lung, and Blood Institute | Gunze Limited | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tissue Engineered Vascular Graft","moa":"Vascular tissue","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nationwide Children\u2019s Hospital \/ National Heart, Lung, and Blood Institute | Gunze Limited | National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Nationwide Children\u2019s Hospital \/ National Heart, Lung, and Blood Institute | Gunze Limited | National Institutes of Health"},{"orgOrder":0,"company":"Yipinhong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Alpradil","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Yipinhong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yipinhong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yipinhong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Alpradil","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Aires Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aires Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aires Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aires Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Aires Pharmaceuticals | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mayo Clinic \/ Aires Pharmaceuticals | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Aires Pharmaceuticals | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"TheraVasc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TheraVasc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TheraVasc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TheraVasc \/ Undisclosed"},{"orgOrder":0,"company":"CoreRx","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CoreRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CoreRx \/ JanOne","highestDevelopmentStatusID":"8","companyTruncated":"CoreRx \/ JanOne"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Alliance Global Partners"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"SPYR Technologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ SPYR Technologies","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ SPYR Technologies"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"Adrian Hernandez","sponsor":"National Heart, Lung, and Blood Institute | Aires Pharmaceuticals | University of Vermont | Universit\u00e9 de Montr\u00e9al | Mayo Clinic | Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Adrian Hernandez","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Adrian Hernandez \/ National Heart, Lung, and Blood Institute | Aires Pharmaceuticals | University of Vermont | Universit\u00e9 de Montr\u00e9al | Mayo Clinic | Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Adrian Hernandez \/ National Heart, Lung, and Blood Institute | Aires Pharmaceuticals | University of Vermont | Universit\u00e9 de Montr\u00e9al | Mayo Clinic | Massachusetts General Hospital"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Balovaptan","moa":"Vasopressin V1a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"CardioKine","sponsor":"Cardiokine Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CardioKine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CardioKine \/ Cardiokine Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"CardioKine \/ Cardiokine Biopharma"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"XC001","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"XC001","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Renaissance Capital"},{"orgOrder":0,"company":"Longeveron","sponsor":"National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Lomecel-B","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG0001","moa":"VEGF-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"AZD8601","moa":"VEGF-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AZD8601","moa":"VEGF-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Kuopio University Hospital","sponsor":"Queen Mary University of London | University College, London | Medical University of Vienna | Servicio Madrile\u00f1o de Salud | FinVector Vision Therapies | \u015al\u0105ski Uniwersytet Medyczny w Katowicach | Rigshospitalet | Euram","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FINLAND","productType":"Virus-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Adenovirus Vascular Endothelial Growth Factor D","moa":"VEGF-D","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kuopio University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kuopio University Hospital \/ Queen Mary University of London | University College, London | Medical University of Vienna | Servicio Madrile\u00f1o de Salud | FinVector Vision Therapies | \u015al\u0105ski Uniwersytet Medyczny w Katowicach | Rigshospitalet | Euram","highestDevelopmentStatusID":"8","companyTruncated":"Kuopio University Hospital \/ Queen Mary University of London | University College, London | Medical University of Vienna | Servicio Madrile\u00f1o de Salud | FinVector Vision Therapies | \u015al\u0105ski Uniwersytet Medyczny w Katowicach | Rigshospitalet | Euram"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alberta Innovates Health Solutions | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alberta Innovates Health Solutions | Canadian Institutes of Health Research","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ Alberta Innovates Health Solutions | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Canadian Institutes of Health Research | The George Institute for Global Health (Sydney, Australia)","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Canadian Institutes of Health Research | The George Institute for Global Health (Sydney, Australia)","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Canadian Institutes of Health Research | The George Institute for Global Health (Sydney, Australia)"},{"orgOrder":0,"company":"Vascular Insights, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Tetradecyl Sulfate","moa":"Vitamin K-dependent protein C (PROC)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vascular Insights, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vascular Insights, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vascular Insights, LLC \/ Undisclosed"},{"orgOrder":0,"company":"North Texas Veterans Healthcare System","sponsor":"National Institutes of Health | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Niacin","moa":"VLDL\/LDL synthesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"North Texas Veterans Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North Texas Veterans Healthcare System \/ National Institutes of Health | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"North Texas Veterans Healthcare System \/ National Institutes of Health | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levoamlodipine","moa":"Voltage-dependent L-type calcium channel subunit alpha-1C; Voltage-dependent L-type calcium channel subunit alpha-1D; Nitric oxide synthase 3; Nitric oxide synthase, inducible","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"||Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Aisa Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lacidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lercanidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lercanidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BMS-919373","moa":"Voltage-gated potassium channel Kv1.5 (KCNA5)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BMS-919373","moa":"Voltage-gated potassium channel Kv1.5 (KCNA5)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Febuxostat","moa":"Xanthine dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Febuxostat","moa":"Xanthine dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cytori Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytori Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytori Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cytori Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spaulding Rehabilitation Hospital","sponsor":"BioSensics | MGH Institute of Health Professions | Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Spaulding Rehabilitation Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Rehabilitation Hospital \/ BioSensics | MGH Institute of Health Professions | Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Spaulding Rehabilitation Hospital \/ BioSensics | MGH Institute of Health Professions | Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"Medtronic Cardiac Rhythm and Heart Failure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medtronic Cardiac Rhythm and Heart Failure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medtronic Cardiac Rhythm and Heart Failure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medtronic Cardiac Rhythm and Heart Failure \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Undisclosed"},{"orgOrder":0,"company":"Allrock Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"ROC-101","moa":"ROCK","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Allrock Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Allrock Bio \/ Versant Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allrock Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Anfibatide","moa":"Platelet glycoprotein Ib alpha chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Allrock Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ROC-101","moa":"ROCK 1 | ROCK 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Allrock Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allrock Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allrock Bio \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"REGN7508","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HRS-5632","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"XTR004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Rohto Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rohto Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rohto Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rohto Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai IxCell Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai IxCell Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai IxCell Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai IxCell Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Vardenafil Hydrochloride","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Respira Therapeutics \/ Gossamer Bio","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Gossamer Bio"}]

    Find Drugs for Cardiology/Vascular Diseases in Phase II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Seqens

                            France
                            CPhI WW Frankfurt
                            Booth #11.0C76
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

                            Lead Product(s) : Protheracytes

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : CellProthera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing

                            Details : ProtheraCytes is an autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack.

                            Product Name : Protheracytes

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 20, 2025

                            Lead Product(s) : Protheracytes

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : CellProthera

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Seqens Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novasep

                            Germany
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV1/SERCA2a,AAV1-SERCA2a

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Celladon

                            Deal Size : $5.4 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Novasep Signs €4.7m Biomanufacturing Deal with Biotech

                            Details : Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.

                            Product Name : Mydicar

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : AAV1/SERCA2a,AAV1-SERCA2a

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Celladon

                            Deal Size : $5.4 million

                            Deal Type : Agreement

                            Axplora Novasep

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum Toxin A

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin...

                            Details : In a post hoc analysis of CABG patients aged 65 years and older treated with 125 units of AGN-151607, a botulinum toxin type A, is a novel investigational neurotoxin the study found a greater risk reduction at 51 percent compared to placebo (nominal p<0....

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 07, 2022

                            Lead Product(s) : Botulinum Toxin A

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Ataciguat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Rancho Santa Fe Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat

                            Details : This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countr...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 17, 2021

                            Lead Product(s) : Ataciguat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Rancho Santa Fe Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Pa...

                            Details : Elezanumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 16, 2020

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ever Pharma

                            Austria
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

                            Lead Product(s) : Cerebrolysin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : VASCage GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE

                            Details : Cerebrolysin is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stroke.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 11, 2019

                            Lead Product(s) : Cerebrolysin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : VASCage GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Ever Pharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGN-151607

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Particip...

                            Details : AGN-151607 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 19, 2018

                            Lead Product(s) : AGN-151607

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SAR407899

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina...

                            Details : SAR407899 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Coronary Artery Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2017

                            Lead Product(s) : SAR407899

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalbavancin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treat...

                            Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endocarditis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 11, 2017

                            Lead Product(s) : Dalbavancin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Alirocumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents Wit...

                            Details : Alirocumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 07, 2016

                            Lead Product(s) : Alirocumab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth